Engineered Probiotic Bacteria Deliver Thymosin Alpha-1 Orally and Boost T Cell Immunity in Mice
Bifidobacterium bacteria engineered to produce thymosin alpha-1 significantly boosted T cell numbers and immune function in mice when given orally, offering a potential alternative to injectable thymosin therapy.
Quick Facts
What This Study Found
Researchers engineered Bifidobacterium longum bacteria to produce human thymosin alpha-1 (Tα1), then fed these bacteria to mice orally every other day for two weeks. Compared to control bacteria, the Tα1-producing bacteria significantly increased CD3+CD4+ and CD3+CD8+ T cells in the blood, spleen, and thymus, and boosted CD4+CD8+ cells in the thymus and spleen.
The immune-stimulating cytokines IFN-γ and IL-12 were significantly elevated in serum, while TNF-α and IL-4 were unchanged — indicating selective activation of the Th1 (cellular immunity) pathway. After three months of treatment, the mice showed thymic hyperplasia (enlarged thymus) and lymph node enlargement, confirming sustained immune organ growth from oral delivery.
Key Numbers
Oral dosing every other day for 2 weeks · significant increases in CD4+ and CD8+ T cells · IFN-γ and IL-12 elevated · TNF-α and IL-4 unchanged · thymic hyperplasia and lymph node enlargement at 3 months · 0.2% L-arabinose induction
How They Did This
The researchers cloned the human thymosin alpha-1 gene into Bifidobacterium longum using an arabinose-inducible expression system. BALB/c mice received oral doses of the engineered bacteria (pre-induced with 0.2% L-arabinose) every other day for two weeks. Controls received bacteria transformed with an empty vector or normal saline. T cell populations were measured by flow cytometry in blood, spleen, and thymus. Serum cytokines (IFN-γ, IL-12, TNF-α, IL-4) were quantified. Long-term effects on thymus and lymph node morphology were assessed after three months.
Why This Research Matters
Thymosin alpha-1 is an established immune-boosting peptide used clinically to treat immune deficiency and as an adjunct in hepatitis B and cancer therapy — but it must be given by injection. Converting it to an oral medication delivered by a probiotic bacterium could dramatically improve patient compliance and reduce side effects. This proof-of-concept in mice shows that a living bacterial delivery system can successfully produce and release a therapeutic peptide in the gut, where it stimulates systemic immune responses.
The Bigger Picture
Using engineered bacteria as living drug factories is an exciting frontier in drug delivery. Bifidobacterium is particularly attractive because it's a normal inhabitant of the human gut and is already used in probiotics. If this approach works for thymosin alpha-1, it could be applied to other therapeutic peptides that currently require injection — potentially transforming how immune-modulating peptide therapies are administered. The concept bridges the worlds of synthetic biology, probiotics, and peptide therapeutics.
What This Study Doesn't Tell Us
This is a mouse study with no human data. The long-term safety of oral genetically modified bacteria is not well characterized. The thymic hyperplasia and lymph node enlargement observed at three months could potentially be concerning if they represent immune over-stimulation. The study does not quantify how much Tα1 actually reaches systemic circulation, and the mechanism of absorption from the gut is not fully characterized. Regulatory hurdles for genetically modified organisms as drug delivery vehicles are substantial.
Questions This Raises
- ?Could this probiotic delivery system be adapted for other therapeutic peptides that currently require injection?
- ?Is the thymic hyperplasia observed at three months a beneficial effect or a sign of immune over-stimulation that could be harmful long-term?
- ?Would this engineered probiotic approach survive the human digestive system and produce enough thymosin alpha-1 to be clinically effective?
Trust & Context
- Key Stat:
- Oral probiotic → systemic T cell boost Mice fed engineered Bifidobacterium producing thymosin alpha-1 showed significantly increased CD4+ and CD8+ T cells in blood, spleen, and thymus compared to controls
- Evidence Grade:
- This study is graded as preliminary because it was conducted entirely in mice. While the immune-boosting effects were consistent and multi-organ, no human testing has been performed, and the concept of using genetically modified bacteria as oral peptide delivery vehicles remains early-stage.
- Study Age:
- Published in 2013, this is an older study. The concept of engineered probiotic drug delivery has advanced significantly since then, but the specific Tα1-Bifidobacterium combination does not appear to have progressed to human trials.
- Original Title:
- Thymosin alpha-1-transformed Bifidobacterium promotes T cell proliferation and maturation in mice by oral administration.
- Published In:
- International immunopharmacology, 15(3), 646-53 (2013)
- Authors:
- Shao, Congwen, Tian, Guojun, Huang, Yuanjian(2), Liang, Wenying, Zheng, Hang, Wei, Jiannan, Wei, Cheng, Yang, Cuilan, Wang, Hong, Zeng, Weisen
- Database ID:
- RPEP-02282
Evidence Hierarchy
Frequently Asked Questions
What is thymosin alpha-1 and what is it used for?
Thymosin alpha-1 (Tα1) is a naturally occurring peptide produced by the thymus gland that plays a key role in immune system development and function. It's used clinically as an injectable immune booster, primarily in Asia and Europe, for conditions including hepatitis B, hepatitis C, certain cancers, and immune deficiency. Its main limitation is that it must be given by injection.
How does a probiotic bacterium deliver a peptide drug?
The researchers inserted the human gene for thymosin alpha-1 into Bifidobacterium longum, a common gut probiotic. When activated by a sugar called L-arabinose, the bacteria produce the peptide inside their cells. When the mice eat the bacteria, the Tα1 is released in the gut and somehow reaches the immune system — boosting T cell production in the blood, spleen, and thymus. The exact mechanism of how the peptide crosses from the gut into the bloodstream was not fully characterized.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-02282APA
Shao, Congwen; Tian, Guojun; Huang, Yuanjian; Liang, Wenying; Zheng, Hang; Wei, Jiannan; Wei, Cheng; Yang, Cuilan; Wang, Hong; Zeng, Weisen. (2013). Thymosin alpha-1-transformed Bifidobacterium promotes T cell proliferation and maturation in mice by oral administration.. International immunopharmacology, 15(3), 646-53. https://doi.org/10.1016/j.intimp.2012.12.031
MLA
Shao, Congwen, et al. "Thymosin alpha-1-transformed Bifidobacterium promotes T cell proliferation and maturation in mice by oral administration.." International immunopharmacology, 2013. https://doi.org/10.1016/j.intimp.2012.12.031
RethinkPeptides
RethinkPeptides Research Database. "Thymosin alpha-1-transformed Bifidobacterium promotes T cell..." RPEP-02282. Retrieved from https://rethinkpeptides.com/research/shao-2013-thymosin-alpha1transformed-bifidobacterium-promotes
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.